MK-677 cost in 2026: why the cheap oral research chemical isn’t actually cheap

Most peptide cost questions are really injection-cost questions: a vial, a compounding pharmacy, a monthly subscription. MK-677 breaks that pattern. Ibutamoren is an oral, non-peptide small molecule — it comes as a capsule or a flavored dropper liquid, taken once a day, with no needle anywhere in the picture.^[1] That single fact reshapes its whole price structure. There is no per-syringe math, no injectable-compounding fee, and — the part the supplement copy never spells out — almost no legitimate pharmacy route at all. What you’re actually pricing when you search “MK-677 cost” is a cheap oral research chemical, and the low number on the bottle is hiding the costs that matter.

Why there is no “real” pharmacy price

Start with the question that quietly answers all the others: where can you legitimately buy it? For an injectable like sermorelin, the answer is a telehealth clinician and a licensed compounding pharmacy — which is why that molecule has a clean, quotable monthly price. MK-677 has no equivalent. It was developed by Merck, carried through human trials, and then never approved or marketed as a medicine; it remains an investigational compound with no FDA-cleared product and no official dose.^[1] With nothing for a pharmacy to compound from a label, the prescription-and-pharmacy channel that prices the injectable peptides simply doesn’t exist here.

So the supply collapses, almost entirely, into the gray market: websites that sell ibutamoren as a powder, capsule or oral solution labeled “for research use only, not for human consumption.” That disclaimer is doing legal work, but it’s also doing pricing work — it’s the reason the number looks so much lower than a telehealth peptide. You’re not getting a discount on the same product; you’re buying a fundamentally different, unregulated one.

What it actually costs: per bottle and per milligram

Because the product is oral, the gray market prices it the way it prices any research chemical — by the bottle and, implicitly, per milligram. Two common formats dominate: capsules, typically sold as a 30-count bottle at a fixed per-capsule strength (often in the 10–25 mg range), and a dropper liquid, usually a 30 mL bottle dosed at a stated milligrams-per-millilitre. As of mid-2026, a single 30-day oral bottle commonly lands somewhere in the low tens of dollars — very roughly the $40–$90 band, with the spread driven by total milligram content, format, and how aggressively a seller discounts bulk orders. Treat that as an order-of-magnitude figure to confirm against current listings, not a quote.

Translate it to a monthly view and the contrast is the whole story. A once-daily oral dose from one of those bottles can work out to well under what a compounded injectable peptide costs per month — often a small fraction of the roughly $120–$300 a month that compounded sermorelin runs through telehealth, a comparison we lay out in the peptide therapy cost overview. On a pure per-milligram basis it is one of the cheapest things in the entire growth-hormone-secretagogue category. That cheapness is real — and it is also exactly the trap.

The costs the sticker hides

Three of them, and none shows up on the checkout page. The first is content and purity risk. Research-chemical bottles sit outside the prescription-and-compounding system, so nobody independent is verifying identity, dose, or contamination. The clearest read on that hazard comes from the adjacent, far-better-studied gray market for GLP-1 drugs: a 2024 market-surveillance study that actually purchased and laboratory-tested semaglutide sold online without a prescription found unregistered sellers, orders that never arrived, and analyzed contents that diverged from the label, including impurities and dose mismatches.^[2] An oral “research” ibutamoren bought the same way carries the same structural exposure — you are buying an unknown, not a cheaper known.

The second hidden cost is no prescriber oversight. MK-677 is not a benign molecule to self-administer blind: in human trials it consistently raised fasting blood glucose and reduced insulin sensitivity, and a hip-fracture trial was halted early over a heart-failure safety signal — details we cover in MK-677 side effects. Buying it as a research chemical means there is no clinician screening for the metabolic and cardiac risks, no baseline labs, and no one adjusting the dose. The third is regulatory and competitive status: it is a non-approved investigational drug, and as a growth-hormone secretagogue it is prohibited in sport under the World Anti-Doping Agency code — a cost that is invisible until a tested athlete pays it.

So is MK-677 “worth” the low price?

That depends entirely on what the price is buying, and here the evidence sets the ceiling. MK-677 reliably raises growth hormone and IGF-1 — in healthy older adults a 2-year randomized trial lifted IGF-1 toward young-adult levels and added a little lean mass.^[3] But the same controlled trials did not show that those biomarker moves translated into greater strength, physical function, cognition or recovery. Paying a low per-milligram price for a compound whose downstream benefits are unproven isn’t automatically a bargain — it’s a low price for a biomarker effect, not an outcome. We grade that full evidence base in the MK-677 evidence review, and you can see where it sits against other compounds in our peptide evidence matrix.

If the appeal was the convenience of an oral, the honest comparison is against the injectable it’s usually weighed against. An injectable GHRH analog has a real prescription-and-pharmacy route, a clinician, and a quotable price — MK-677 trades all of that away for a cheaper, unregulated bottle. We put the two side by side, on both cost and oversight, in MK-677 vs sermorelin, and the practical dosing the trials actually used is in our MK-677 dosage guide.

The honest bottom line

MK-677 is cheap because it is sold cheap: an oral research chemical with a low per-milligram sticker, no prescription, and no pharmacy standing behind it. The number you see — often a few tens of dollars for a month’s oral supply, mid-2026 — is genuinely low, but it prices only the powder. It does not price the unverified content and dose, the absence of any prescriber screening for its metabolic and cardiac risks, or its status as a non-approved, sport-banned investigational drug. The smart move isn’t to chase the lowest milligram price; it’s to weigh that price against an evidence base that, so far, supports a biomarker effect and not an outcome. To compare the legitimate, prescribed peptide options on price and care model instead, see our peptide therapy provider comparison, and read where to get peptides safely before you buy anything from a “research only” website. (To be explicit: this is a cost-versus-risk analysis, not a recommendation to source MK-677 this way.)